char = T;code = 84
Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels.char = D;code = 68
Publication: Nat. Med. 2001 Apr ;7(4)::471-7.
Publication Date: 2001 Apr
Study Author(s): Gribkoff, V K;Starrett, J E;Dworetzky, S I;Hewawasam, P;Boissard, C G;Cook, D A;Frantz, S W;Heman, K;Hibbard, J R;Huston, K;Johnson, G;Krishnan, B S;Kinney, G G;Lombardo, L A;Meanwell, N A;Molinoff, P B;Myers, R A;Moon, S L;Ortiz, A;Pajor, L;Pieschl, R L;Post-Munson, D J;Signor, L J;Srinivas, N;Taber, M T;Thalody, G;Trojnacki, J T;Wiener, H;Yeleswaram, K;Yeola, S W;
Institution: Neuroscience Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut, USA.
[email protected]
Shortcut link to this study:
During ischemic stroke, neurons at risk are exposed to pathologically high levels of intracellular calcium (Ca++), initiating a fatal biochemical cascade. To protect these neurons, we have developed openers of large-conductance, Ca++-activated (maxi-K or BK) potassium channels, thereby augmenting an endogenous mechanism for regulating Ca++ entry and membrane potential. The novel fluoro-oxindoles BMS-204352 and racemic compound 1 are potent, effective and uniquely Ca++-sensitive openers of maxi-K channels. In rat models of permanent large-vessel stroke, BMS-204352 provided significant levels of cortical neuroprotection when administered two hours after the onset of occlusion, but had no effects on blood pressure or cerebral blood flow. This novel approach may restrict Ca++ entry in neurons at risk while having minimal side effects.
How is this determined?
